A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2016
At a glance
- Drugs Peficitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 08 Apr 2016 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
- 24 Sep 2014 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 03 Mar 2014 Planned End Date changed from 1 Dec 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.